CSCIF (Cosciens Biopharma) Quality Rank


CSCIF Cosciens Biopharma Inc CSCIF
60 GF Score
Price $2.13
GF Value $2.39
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Cosciens Biopharma Quality Rank Related Terms

CSCIF
60GF Score
Cosciens Biopharma Inc CSCIF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Quality Rank:
  • GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score

Get the complete analysis for CSCIF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price
$2.39
GF Value